Drug Trial Radar · NCT07881835
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Oct 22, 2026
Primary completion
Feb 16, 2029
Study completion Feb 16, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 4, multicenter, open-label, single-arm study evaluating the safety and efficacy of elranatamab monotherapy in adult participants with relapsed or refractory multiple myeloma in India. Eligible participants must have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. All enrolled participants will receive elranatamab; there is no comparator or control arm. Approximately 100 participants are planned to be enrolled across approximately 10 study sites in India. Study assessments will include evaluation of disease response and monitoring of adverse events in accordance with the study protocol.
Conditions
- Relapsed/Refractory Multiple Myeloma
- Multiple Myeloma
Interventions
ElranatamabDrug
Elranatamab is a bispecific T-cell-engaging monoclonal antibody targeting B-cell maturation antigen (BCMA) and CD3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: From first dose of elranatamab through the End-of-Treatment visit -approximately 12 months after enrollment)
- Laboratory AbnormalitiesTime frame: From first dose of elranatamab through the End-of-Treatment visit -approximately 12 months after enrollment)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.